UK: Lyme Disease - Small Bite, Big Threat

Last Updated: 28 August 2014
Article by Karen Taylor

The theme of the World Health Day in April 2014 was vector-borne diseases- 'Small Bite: Big Threat'. For many people this conjured up thoughts of Malaria, Dengue or West Nile Virus but, few people in the UK are aware that the UK's most common vector-borne human infection is Lyme disease.[i]

Although Lyme disease in endemic in the UK few people actually know what it is. Caught early and treated with antibiotics, years of debilitating health problems can be prevented. Yet, many general practitioners (GPs) lack knowledge of the disease and the recommended diagnostic tests lack the sensitivity and specificity to detect early cases or late manifestations of the disease, such as chronic or autoimmune-related infections. As a result the incidence of the disease is seriously underestimated with many cases going undiagnosed or misdiagnosed.

Lyme disease is an infection caused by a family of genetically diverse bacteria called Borrelia burgdorferi. The bacteria are transmitted to humans by ticks, small spider-like insects which live in long grass, woods, and other damp vegetation where they feed on the blood of deer and other mammals. Much like the organism that causes Malaria, the bacteria take different forms throughout their lifecycle, which makes them difficult to detect and leads to a diverse range of symptoms. Symptoms are initially mild and limited to the locality of the bite, but if left untreated chronic Lyme disease often develops which can have devastating, long term effects.

Patients treated with appropriate antibiotics in the early stages of Lyme disease usually recover rapidly and completely. Nevertheless, one of the greatest barriers to effective, early treatment remains GPs lack of awareness of the complexity of the disease, or the diverse symptoms with which patients may present. As a result, too many patients suffer the long-term or chronic impact of Lyme disease and are misdiagnosed with multiple sclerosis, chronic fatigue syndrome and arthritis.

The incidence of Lyme borreliosis has been monitored in England and Wales by the Health Protection Agency (HPA), now part of Public Health England (PHE), since 1996. Since 2010, every microbiology laboratory (including those in the private sector) in England is required to notify all laboratory diagnoses of borreliosis to the Health Protection Agency (now Public Health England). Laboratory-confirmed reports of Lyme disease have risen steadily since surveillance began. In 2011 there were 959 confirmed cases and in 2012, 998[ii]. In acknowledging the significant difficulties in diagnosing Lyme disease, PHE suggest the truer figure is likely to be around 2,000 - 3,000 new cases each year. However, Lyme disease patient groups believe the number to be closer to 15,000 cases a year.[iii]

Factors that may have contributed to the increase include the geographical migration of ticks as a result of successive mild winters, an explosion in the deer population and increased recreational travel to high endemic areas, including walking, trekking, and mountain biking in the UK and abroad.

There are a number of significant challenges in diagnosing Lyme disease:

  • patients may not be aware that they have been infected as ticks are typically invisible to the naked eye and inject a local anaesthetic-like substance so bite goes unnoticed (the longer the tick is in place, the higher the risk of infection)
  • Lyme disease is difficult for GPs to diagnose as the most common, and in some cases only manifestation is erythema migrans (known as the'bull's eye' rash) which appears between three and 30 days after a bite. However around 30 to 40 per cent of patients do not present with a rash (not the 90 per cent cited on the NHS website[iv]), but present with a range of non-specific 'flu-like symptoms, tiredness, headaches, arthralgia (joint pains) and myalgia (muscle aches). Even where there is a rash, this varies in appearance and size (from two to 30 centimeters), expanding over several days or weeks
  • there is no definitive laboratory test for Lyme disease. Since June 2012, the Lyme disease testing service in the UK has been carried out by the Rare and Imported Pathogens Laboratory (RIPL) in Porton Down using a two-tier testing system recommended by American and European authorities comprising: the C6 antigen based enzyme linked immunosorbent assay (ELISA) test; followed by the immuno-blotting (western blotting) test. If the results of both the ELISA test and the Western Blot test are positive, a confident diagnosis of Lyme disease can usually be made.[v]

The manufacturers of both the ELISA and Western Blot tests, however, clearly state that a negative result should NOT be taken as meaning you don't have Lyme disease. Indeed if an initial test is negative, but symptoms persist, there should be a repeat sample 3-4 weeks after the initial test. 

In 2013, PHE launched a series of leaflets to raise awareness of Lyme disease and other tick-borne illnesses among health professionals and the public[vi] and in May this year issued guidelines for referral pathways for patients suspected of having Lyme disease[vii]. This guidance clarifies that the significance of any result, negative or positive, should be interpreted carefully by clinicians in the overall context of the patient's clinical symptoms and exposure risk to ticks. Specifically, patients seen by a GP with an Erythema migrans rash at the time of consultation should be treated with antibiotics indicated for Lyme disease; while patients without a rash but with symptoms suggestive of Lyme disease, and a credible risk of tick exposure, should have serum taken and sent to an NHS laboratory for testing. 

For patients there is currently no vaccine available to prevent Lyme disease. Meanwhile, clinicians have to interpret symptoms which may not match the "classic symptoms" of Lyme and rely on tests which lack sensitivity and specificity. As a result there is some way to go before Lyme's disease can be diagnosed and treated effectively. Work is on-going to equip the GP community to diagnose better and instigate earlier treatment. However, in the absence of an accurate diagnostic test, raising public awareness about risks and prevention and how to identify symptoms early is key if we are to reduce the debilitating effects of this relatively rare, but potentially devastating disease.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions